

IN THE CLAIMS:

The following listing of claims will replace all prior versions and listings of the claims in this application:

Claims 1-13 (Canceled)

Claim 14 (Previously Presented): A composition for the treatment of asthma, the composition comprising:

montelukast sodium;
an antihistamine selected from the group consisting of cetirizine, fexofenadine, and combinations thereof; and
a sympathomimetic bronchodilator.

Claim 15 (Original): The composition of claim 14, wherein said sympathomimetic bronchodilator is albuterol.

Claims 16 (Withdrawn): A method for treating asthma comprising the steps of:
preparing a composition comprising:

a first receptor antagonist in the amount of between about 4.0 mg and about 20.0 mg;
a second receptor antagonist in the amount of between about 2.5 mg and about 180.0 mg, said second receptor antagonist being different from said first receptor antagonist;
an adrenergic bronchodilator in the amount of between about 4.0 mg and about 8.0 mg; and
administering said composition to a patient.

Claim 17 (Withdrawn): The method of Claim 16, wherein said first receptor antagonist and said second receptor antagonist are selected from the group consisting of leukotriene receptor antagonists and histamine receptor antagonists.

Claim 18 (Withdrawn): The method of Claim 16, wherein said adrenergic bronchodilator is a β_2 -adrenergic bronchodilator.

Claims 19-22 (Canceled)

Claim 23 (Previously Presented): A composition for the treatment of asthma, the composition comprising:

- (a) a leukotriene receptor antagonist;
- (b) a histamine receptor antagonist selected from the group consisting of cetirizine hydrochloride, and fexofenadine and combinations thereof; and
- (c) an adrenergic bronchodilator.

Claim 24 (Previously Presented): The composition of claim 23, wherein the adrenergic bronchodilator is a β_2 -adrenergic bronchodilator.

Claim 25 (Previously Presented): The composition of claim 23, wherein the histamine receptor antagonist is a histamine receptor H_1 -receptor antagonist.

Claim 26 (Canceled)

Claim 27 (Previously Presented): The composition of claim 23, wherein the leukotriene receptor antagonist is selected from the group consisting of:

montelukast sodium, zafirlukast sodium, and combinations thereof.

Claim 28 (Canceled)

Claim 29 (Canceled)

Claim 30 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is cetirizine hydrochloride;
- (b) The leukotriene receptor antagonist is montelukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 31 (Canceled)

Claim 32 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is fexofenadine;
- (b) The leukotriene receptor antagonist is montelukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 33 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is cetirizine hydrochloride;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 34 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is loratadine;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 35 (Withdrawn): The composition of claim 23, wherein

- (a) The histamine receptor antagonist is fexofenadine;
- (b) The leukotriene receptor antagonist is zafirlukast sodium; and
- (c) The adrenergic broncodilator is albuterol sulfate.

Claim 36 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 23.

Claim 37 (Withdrawn): The method of claim 36, wherein the amount of the histamine receptor antagonist in the composition is between about 2.5 mg and about 180 mg.

Claim 38 (Withdrawn): The method of claim 36, wherein the amount of the leukotriene receptor antagonist in the composition is between about 4 mg and about 20 mg.

Claim 39 (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is between about 4 mg and about 8 mg.

Claim 40 (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 2 mg.

Claim 41 (Withdrawn): The method of claim 36, wherein the amount of the adrenergic broncodilator in the composition is about 0.1mg/kg of the patient's body weight.

Claim 42 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 29.

Claim 43 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 30.

Claim 44 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 31.

Claim 45 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 32.

Claim 46 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 33.

Claim 47 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 34.

Claim 48 (Withdrawn): A method for treating asthma, the method comprising administering to a patient in need thereof the composition of claim 35.

Claim 49 (New): A composition for the treatment of asthma, the composition comprising:

a first receptor antagonist and a second receptor antagonist, said first and second receptor antagonists being independently selected from the group consisting of leukotriene receptor antagonists, histamine receptor antagonists, and combinations thereof; and

an adrenergic bronchodilator, the adrenergic bronchodilator including an immediate release portion and an extended release portion.

Claim 50. (New): The composition of Claim 49, wherein said adrenergic bronchodilator is a beta₂-adrenergic bronchodilator.

Claim 51. (New): The composition of Claim 50, wherein said beta₂-adrenergic bronchodilator is albuterol.

Serial No. 09/825,258

Claim 52. (New): The composition of Claim 49, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium, zafirlukast sodium, and combinations thereof.

Claim 53. (New): The composition of Claim 49, wherein said histamine receptor antagonist is a histamine H₁-receptor antagonist.

Claim 54. (New): The composition of Claim 53, wherein said histamine H₁-receptor antagonist is selected from the group consisting of cetirizine hydrochloride, loratadine, fexofenadine, and combinations thereof.

Claim 55. (New): A composition for treatment of asthma, the composition comprising:

a first receptor antagonist comprising a leukotriene receptor antagonist;
a second receptor antagonist comprising a histamine receptor antagonist; and
an adrenergic bronchodilator, the adrenergic bronchodilator including an immediate release portion and an extended release portion.

Claim 56. (New): The composition of Claim 55, wherein said adrenergic bronchodilator is a beta₂-adrenergic bronchodilator.

Serial No. 09/825,258

Claim 57. (New): The composition of Claim 56, wherein said β_2 -adrenergic bronchodilator is albuterol.

Claim 58. (New): The composition of Claim 55, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium, zafirlukast sodium, and combinations thereof.

Claim 59. (New): The composition of Claim 55, wherein said histamine receptor antagonist is a histamine H1-receptor antagonist.

Claim 60. (New): The composition of Claim 59, wherein said histamine H1-receptor antagonist is selected from the group consisting of cetirizine hydrochloride, loratadine, fexofenadine, and combinations thereof.

Claim 61. (New): A composition for the treatment of asthma, the composition comprising:

montelukast sodium;

an antihistamine selected from the group consisting of cetirizine, loratadine, fexofenadine, and combinations thereof; and

an adrenergic bronchodilator, the adrenergic bronchodilator including an immediate release portion and an extended release portion.

Serial No. 09/825,258

Claim 62. (New): The composition of Claim 61, wherein said adrenergic bronchodilator is albuterol.